Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
Arcutis Biotherapeutics reports company developments as a commercial-stage biopharmaceutical company focused on immuno-dermatology and medical dermatology. Its recurring updates center on ZORYVE (roflumilast) cream and foam, a topical PDE4 inhibitor portfolio used across inflammatory skin diseases including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.
Company news commonly covers ZORYVE net product revenue, demand trends for branded non-steroidal topical treatments, clinical data from dermatology studies, FDA submissions tied to potential label expansion, medical-meeting presentations, guideline references, sales-force and commercial updates, conference participation, and equity grants made under Nasdaq inducement-grant rules.
Arcutis Biotherapeutics has submitted a New Drug Application (NDA) for roflumilast cream targeting plaque psoriasis. They are also initiating Phase 3 trials for roflumilast foam in scalp and body psoriasis and atopic dermatitis. The company holds a strong financial position with approximately $370 million in cash and securities, sufficient to fund operations into 2023. However, R&D and G&A expenses have significantly increased, resulting in a net loss of $57 million for Q3 2021. Positive outcomes from ongoing trials could pave the way for multiple product launches within 2022.
Arcutis Biotherapeutics (Nasdaq: ARQT) has submitted a New Drug Application (NDA) to the FDA for its non-steroidal treatment, roflumilast cream, aimed at treating plaque psoriasis. This cream is poised to be the first topical PDE4 inhibitor if approved. In Phase 3 studies, roflumilast cream showed significant improvements over placebo in key endpoints related to psoriasis treatment and was well-tolerated. The treatment offers a promising option for patients, addressing challenges posed by current therapies.
Arcutis Biotherapeutics (ARQT) announced promising Phase 3 results for its topical roflumilast cream, demonstrating significant reductions in itch severity and burden in chronic plaque psoriasis patients. Data revealed that quality of life improvements began as early as week two. Roflumilast cream showed a 42.4% success rate in the Investigator Global Assessment compared to 6.1% for the vehicle. Additionally, the Phase 2 studies indicated strong efficacy in seborrheic dermatitis and scalp psoriasis. These findings support the potential of roflumilast as a non-steroidal treatment option.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced a new patent from the U.S. Patent and Trademark Office, enhancing protection for its topical roflumilast formulations aimed at treating psoriasis and other skin conditions. The patent covers the delivery and extended half-life of cream and foam versions of roflumilast, a potent PDE4 inhibitor. CEO Frank Watanabe stated that this patent adds significant protection and validates their dermatology development platform, which is supported by eight existing patents and many pending, projected to last until at least 2037.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced four abstracts on its topical roflumilast program will be presented at the EADV Congress. Roflumilast, a PDE4 inhibitor, is being investigated for treating psoriasis and seborrheic dermatitis. Data from pivotal DERMIS trials show improved efficacy compared to placebo, focusing on alleviating itch severity in chronic plaque psoriasis. Presentation highlights include a Phase 3 study demonstrating the effectiveness of roflumilast cream. The company aims to revolutionize treatment standards in dermatology, with regulatory filings anticipated in late 2021.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced participation in two investor conferences this September. The first is the Morgan Stanley 19th Annual Global Healthcare Conference on September 15, 2021, at 10:15 a.m. EDT, followed by the Cantor Virtual Global Healthcare Conference on September 27, 2021, at 11:20 a.m. EDT. Both events will be accessible via webcast on the company’s Investor website. Arcutis focuses on innovative solutions for immune-mediated dermatological conditions, aiming to enhance treatments for diseases such as plaque psoriasis and atopic dermatitis.
On September 2, 2021, Arcutis Biotherapeutics (Nasdaq: ARQT) appointed Keith R. Leonard Jr. to its Board of Directors, succeeding Ricky Sun, Ph.D., who stepped down for personal reasons. Leonard brings over 25 years of leadership experience in the biopharmaceutical sector, having previously served as CEO of two public companies and as a board member for several others. The management expresses confidence in Leonard's ability to support the company's goals, particularly as it prepares for the potential commercial launch of topical roflumilast, targeting various dermatological conditions.
Arcutis Biotherapeutics (Nasdaq: ARQT) has initiated its Phase 3 clinical trial for topical roflumilast foam (ARQ-154), targeting scalp and body psoriasis, which affects over 8 million U.S. patients. The ARRECTOR study will enroll approximately 420 subjects aged 12 and older, assessing safety and efficacy. Key endpoints include Scalp-Investigator’s Global Assessment success after 8 weeks. Previous trials have indicated roflumilast's effectiveness and safety. The company aims for FDA submission following positive trial results, addressing an unmet need in dermatological treatment.
Arcutis Biotherapeutics (Nasdaq: ARQT) has appointed Bruce Binkowitz as Vice President of Biometrics, bringing over 30 years of drug development experience. He will oversee biometrics activities supporting late-stage clinical programs and regulatory submissions for topical roflumilast in treating psoriasis, atopic dermatitis, and seborrheic dermatitis. The company anticipates its first New Drug Application submission by late 2021, as well as three Phase 3 clinical data readouts in the next 18 months. Arcutis aims to innovate treatments for serious skin disorders.
Arcutis Biotherapeutics (ARQT) has reported a net loss of $42 million for Q2 2021, with total cash and equivalents at $410.9 million, supporting operations into 2023. The company is preparing to submit a New Drug Application for topical roflumilast cream targeting plaque psoriasis by late Q3 or early Q4 2021. Multiple Phase 3 trials for roflumilast formulations are ongoing, with topline data anticipated in 2022. However, there were setbacks with ARQ-252 in chronic hand eczema and vitiligo, leading to its termination.